Strimvelis Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The strimvelis market research report is one of a series of new reports that provides strimveli market statistics, including strimveli industry global market size, regional shares, competitors with a strimveli market share, detailed strimveli market segments, market trends and opportunities, and any further data you may need to thrive in the strimveli industry. This strimveli market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The growth in the forecast period can be attributed to the development of companion diagnostics, broader insurance coverage, expansion into emerging markets, emerging gene therapy competitors, and patient advocacy and support organizations. Major trends in the forecast period include vector development and optimization, nanotechnology for targeted therapy, microrna-based gene therapies, the integration of digital twins, and advancements in lentiviral vectors.

The growing incidence of rare genetic disorders is expected to drive the expansion of the strimvelis market in the future. Rare genetic disorders arise from mutations or alterations in an individual’s DNA and occur infrequently within the general population. The rising prevalence of these disorders can be attributed to advancements in genetic testing, which have improved detection rates, as well as environmental factors and, in some cases, lifestyle choices that may contribute to DNA mutations. Strimvelis, a gene therapy, offers a potential solution for treating rare genetic conditions, particularly adenosine deaminase severe combined immunodeficiency (ADA-SCID). It works by using the patient's own modified stem cells to introduce a functional ADA gene, thus restoring immune function and potentially providing a long-term cure for this life-threatening disorder. For example, a report from the Cystic Fibrosis Trust in September 2023 noted that the number of cystic fibrosis patients registered in the UK surpassed 11,000 in 2022, a notable increase from the previous year. As the prevalence of rare genetic disorders rises, so too does the demand for treatments such as strimvelis.

The continued increase in healthcare expenditure is also set to fuel the growth of the strimvelis market. Healthcare expenditure refers to the total spending on medical services and products within a given period, typically measured annually. The growth in healthcare spending can be attributed to factors such as an aging population, the rising prevalence of chronic diseases, technological advancements in medicine, higher pharmaceutical costs, and expanded access to healthcare services. Increased spending on healthcare plays a vital role in supporting the development, accessibility, and administration of innovative therapies such as strimvelis, which rely on adequate funding to reach patients with rare and life-threatening conditions. For instance, in December 2023, the Centers for Medicare & Medicaid Services reported that healthcare spending in the U.S. grew by 4.1% in 2022, reaching a total of $4.5 trillion, up from a 3.2% increase the previous year. This upward trend in healthcare expenditure is expected to drive further growth in the strimvelis market.

The increasing shift towards personalized medicine is another factor expected to propel the growth of the strimvelis market. Personalized medicine is an approach that tailors treatment plans and healthcare strategies to the specific needs and characteristics of individual patients. This shift is being driven by the growing availability of precision diagnostic tools, a focus on value-based healthcare, and an increasing demand for more targeted and effective treatments that can improve patient outcomes. Strimvelis aligns with the concept of personalized medicine by offering a gene therapy specifically designed for patients with adenosine deaminase severe combined immunodeficiency (ADA-SCID). This therapy uses the patient's own stem cells to deliver a functional copy of the ADA gene, providing a customized treatment option based on the patient’s unique genetic makeup. According to the Personalized Medicine Coalition, 2022 saw the approval of 12 new personalized medicines, accounting for 34% of all newly approved therapies, a notable increase from previous years. As personalized medicine continues to gain traction, it is expected to further drive growth in the strimvelis market.

The key company operating in the strimvelis market is Orchard Therapeutics plc

North America was the largest region in the strimvelis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in strimvelis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the strimvelis market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Strimvelis is a gene therapy developed to treat adenosine deaminase deficiency-severe combined immunodeficiency (ADA-SCID). It works by utilizing a patient's own stem cells, which are collected, genetically modified to correct the defective ADA gene, and then reintroduced into the patient to restore immune function and address ADA-SCID.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Key clinical indications for Strimvelis include primary indications, patient populations, clinical study data, and its mechanism of action. The main use of Strimvelis is for treating Severe Combined Immunodeficiency (SCID) caused by a deficiency in Adenosine Deaminase (ADA). It is provided through hospitals and pharmacies, serving a wide range of end users, including both pediatric and adult patients.

The strimvelis market consists of sales of products including libmeldy, zolgensma, luxturna, roctavian, and skysona. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.